E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.
Louisville pharmacy dispensing compounded weight loss drugs in effort to address shortage
Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of selling unauthorized versions of their drugs. The companies argue that some compounded products are ineffective or even dangerous.
The most and least expensive weight loss drugs, ranked
Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The medications, which belong to the class of drugs called GLP-1s and were popularized by the diabetes treatment Ozempic,
Websites selling compounded weight-loss drugs fail to inform patients of risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the risks associated with these medicines, according to a research letter published on Friday.
Tripling Wegovy dosage leads to more weight loss, Novo Nordisk trial shows
Tripling the dosage of the Wegovy weight-loss drug leads to more weight loss, Novo Nordisk said Friday. The Danish drugmaker announced results from a Phase 3B trial of semaglutide at a 7.2 milligram dosage,
Wegovy at Higher Dose Achieves Greater Weight Loss in Trial
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side effects.
Novo Nordisk says its obesity drug in higher dose shows 20.7% weight loss
Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the results fell short of the weight loss achieved with Eli Lilly's rival drug Zepbound,
Novo Nordisk says higher Wegovy dose caused over 20% weight loss in late-stage trial
Novo Nordisk (NVO) announced Friday that a higher-dose version of its popular obesity therapy, semaglutide, marketed as Wegovy led to 20.7% weight loss over 72 weeks compared to 17.5% weight loss achieved by regular semaglutide in a late-stage trial.
Hosted on MSN12m
Hims vs Ro: Which Weight Loss Program Fits You Best?
Losing weight can feel like climbing a mountain with no clear path. The one-size-fits-all advice—like “eat less, move ...
Metro Times8d
What Is the Ideal Semaglutide Dose for Weight Loss?
The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...
Columbus Monthly9d
Tuning Out Food Noise: Semaglutide Injections Help Patients Achieve Long-Term Weight Loss
Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...
WTOP News4d
Can Microdosing Weight Loss Drugs Like Ozempic Help You Lose Weight?
Compounded versions of semaglutide refer to off-brand versions ... which could have unwanted impacts on your weight loss journey or come with health risks. Does Microdosing Ozempic Really Come ...
‘Ozempic’s biggest night’: How weight loss drugs showed up at the 2025 Golden Globes
Just eight seconds into the start of the 2025 award show season, Nikki Glaser, the host of the 82nd Golden Globes, dubbed the ...
Madison.com10d
6 Best Weight Loss Treatments: Ranking Top Weight Loss Solutions of 2025
Their weight loss programs follow the same philosophy — providing weight loss solutions like compounded GLP-1 (e.g.